The clinical trials operation for Yale Cancer Center remains one of my top priorities for 2011.
Hank Durivage has led our Clinical Trials Office through a host of staff and operational changes needed. In addition to Hank's leadership, I am pleased to announce that Kathleen Uscinski joined Yale Cancer Center and the Yale Center for Clinical Investigation as the Associate Director for Clinical Trials Operations.
Kathy was most recently the Director of the Office of Human Research Protection for Yale School of Medicine and has already hit the ground running with her leadership of operations in the CTO.
Hank will continue as the Associate Director for Clinical Trials and Regulatory Affairs. Please join me in welcoming Kathy to the leadership team.
Closer to Free Bike Ride
Please join your colleagues from Yale Cancer Center and Smilow Cancer Hospital for our first annual Closer to Free Bike Ride on September 10, 2011.
The 25- or 100-mile ride will depart from the Yale Bowl. This is the premier fundraising event to support our cancer care and research efforts. I will be riding with my family, and look forward to seeing many teams of riders from Smilow and Yale. Registration is now open online.
Smilow Cancer Hospital Options for Robotic Surgery Expand
Dr. Charles Cha performed the first robotic distal pancreatectomy/splenectomy for a neuroendocrine tumor at Smilow Cancer Hospital last week. The patient recovered from the operation very well and was able to go home in three days.
Robotic surgery is available at Smilow Cancer Hospital for appropriate patients diagnosed with prostate cancer or gynecological malignancies. Dr. Cha's experience will allow us to expand our robotic surgery program to some patients with gastrointestinal malignancies.
Advanced Vascular Imaging Services Available
Smilow Cancer Hospital is now offering full service non-invasive vascular ultrasound and physiological testing on the second floor of the hospital in the diagnostic imaging suites.
Led by Leslie Scoutt, MD, screening for varicose veins, venous insufficiency, carotid ultrasound, transcranial doppler aortic aneurysms, renal artery stenosis, lower and upper arterial bypass grafts, dialysis access transplant, hepatic/TIPS, portal, mesenteric vascular imaging, lower and upper venous Doppler for DVT, vein mapping, and segmental pressure ABI/PVR is available. To schedule a patient exam, please call (203) 688-2433.
Urologic Surgeons Begin Practice in Smilow
Drs. John Colberg, Harris Foster, and Dinesh Singh are now seeing their patients on the fourth floor of Smilow Cancer Hospital.
Their new phone number for scheduling patients is (203) 200-4822.
Susan Silva has been hired in the Yale Cancer Center director's office as a senior administrative assistant.
Susan joined the cancer center from the Yale School of Management and will support Kevin Vest, Chad Ellis, and Jennifer Mulligan.
In the Clinical Trials Office, Vicky Marler joined the staff as a data manager for the GU team, Stephanie Sellers has been hired as a new data manager for the breast team, and Geraldine Tomassi has taken on the role of a Regulatory Assistant.
Maureen Raucci, RN, BSN has been appointed to the Patient Service Manager position on NP 12. Maureen has been an assistant patient service manager on NP 12 for 2 years and has extensive management experience. She has led several important initiatives on NP 12 to improve patient outcomes and increase nursing satisfaction.
Maeve G. Waldron-Lynch, Kamil Detyniecki, Maysa Abu-Khalaf, and Joachim Baehring are co-authors on a poster presented this week at the
American Academy of Neurology Annual Meeting in Honolulu, Hawaii. The title of their presentation is A Single Institution Experience of Paraneoplastic Neurological Syndromes Associated with Gynecological Cancers.
Tracy Carafeno, RN, MS has been chosen by the American Organization of Nurse Executives (AONE) as a nurse leader fellow for 2011.
Funding and Award Opportunities
Avon Foundation Breast Cancer Research Grants
Proposals may request up to $150,000 total costs per year (this limit is inclusive of 10% indirect costs), for up to 2 years in duration. Thus, the total award budget can be up to $300,000 to cover up to 2 years duration.
Understanding the potential causes of breast cancer and research to develop new preventative strategies
Understanding the role of endogenous and exogenous environmental factors in the development of breast cancer
Understanding whether viruses or infectious agents play a role in breast cancer
Validation of markers/biomarkers of breast cancer risk or that signal different breast states such as parous vs. nulliparous breast (Note: we do not support discovery research. Our funds are directed towards validation, translation or clinical application of markers)
Development of clinically applicable assays or diagnostic tests that are predictive of breast cancer risk or that can be used to monitor changes in breast over time (for example, differentiating healthy breast vs. ADH vs. DCIS vs. IDC)
Understanding how parity and breastfeeding alter breast cancer risk
The Elsa U. Pardee Foundation funds investigators proposing research directed toward identifying new treatments or cures for cancer. The foundation particularly encourages grant applications for a one-year period, which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified.
Yale Cancer Center has the opportunity to nominate a cancer research project that brings together pre-clinical and clinical investigators who are not currently funded together through an external grant. The purpose of the grant is to develop novel approaches to the prevention, detection and treatment of human cancer that requires collaboration of investigators from both the lab and clinic. The Translational Grant is a $600,000 award paid in $200,000 installments over three years. Please contact Roy Herbst if you have a project you would like considered for nomination.
The V Foundation V Scholar Grant
Yale Cancer Center can nominate one researcher for consideration for a V Scholar grant for laboratory based fundamental and translational research. Candidates must have completed two years of fellowship training but have not had more than five years on faculty, or ten years since terminal degree. The V Scholar grant totals $200,000 and is given in two yearly installments. Please contact Dan DiMaio to submit a nomination.
2011 Advanced Clinical Research Award in Breast Cancer funded by The Breast Cancer Research Foundation
The grant is designed to fund investigators who are committed to clinical cancer research and who wish to conduct original research not currently funded. This research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects.
Yale School of Public Health Ovarian Cancer Research Grant
The Yale School of Public Health is pleased to announce a call for applications for the Ovarian Cancer Research Grant. This award is made possible by a generous gift from the Tina Brozman Foundation. The award is to provide funding for a pilot project in ovarian cancer prevention, detection, and survivorship research, which would ultimately lead to national peer-reviewed grants.
Professors, Associate Professors, Assistant Professors, and Research Track faculty of all ranks are eligible to apply. There are no restrictions for citizenship. A one-year grant up to $25,000 will be awarded and will commence on July 1, 2011.
Application Deadline: May 13, 2011
For more information, or to request an application, please email Yong Zhu.
Connecticut Department of Public Health: Tobacco Use
The State of Connecticut, Department of Public Health (DPH) announces the release of a Request for Proposal (DPH RFP # 2011-0917) for tobacco use cessation services in Connecticut, especially targeting populations that have a documented disparate use of tobacco products compared to the general population.
DPH is looking for contractors to provide group and individual tobacco use cessation counseling services to Connecticut residents.
The Donaghue Foundation Program for Research Leadership 2011
The Program for Research Leadership (PRL)
is a Connecticut-focused grant program that will support transdisciplinary teams of health researchers led by a principal investigator who has demonstrated leadership in innovative and useful health research and in transferring knowledge gained from research into clinical and/or public health practice. The overall goal of the program is to fund rigorous health research that incorporates effective approaches to translating research knowledge into practice. The program provides opportunities for the team members to enhance their expertise in transdisciplinary work and knowledge translation. This is a four-year award granting up to $200,000 per year. Total grant award is up to $800,000 (plus 10% indirect costs on an annual basis). The foundation will make one Program for Research Leadership grant award in 2011.
Letter of Intent Deadline: May 26, 2011
Cancer Survivors Day
Yale Cancer Center and Smilow Cancer Hospital will celebrate Cancer Survivors Day on Wednesday, May 25 on Yale's West Campus at 5 PM.
The celebration will feature keynote speaker Ethan Zohn, winner of Survivor Africa and a cancer survivor.
Following the program, guests will gather for a barbecue picnic.
The planning committee would like to have entertainment during dinner. Please contact Emily Fenton
if you know of a local band, or have a patient that participates in a musical group that may be willing to perform for a short set that evening.Thank you in advance for your help and suggestions.
High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.
Varughese J, Cocco E, Bellone S, Bellone M, Todeschini P, Carrara L, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.